Skip to main content
BD10-Q: Quality issue

BDX's Alaris infusion pump business continues to operate under an FDA Consent Decree.

What happened

The company faces significant regulatory risk with its U.S. infusion pump business, with the FDA having authority to halt manufacturing or order recalls. This creates intense pressure to ensure quality, compliance, and supply chain continuity for the product's re-introduction to the U.S. market.

Source

SEC EDGARAug 6, 2026

Quarterly report (Form 10-Q)

BD 10-Q

Filing excerpt

As a result of the CareFusion acquisition, our U.S. infusion pump business is operating under a Consent Decree with the FDA. The Consent Decree authorizes the FDA, in the event of any violations in the future, to order our U.S. infusion pump business to cease manufacturing and distributing products, recall products or take other actions, and order the payment of significant monetary damages if the business subject to the decree fails to comply with any provision of the Consent Decree.

sec.gov/Archives/edgar/data/10795/000001079526000035/bdx-20260630.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Quality issue

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/30
Filed
Aug 6, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
10795
Accession number
0000010795-26-000035
Timeframe
Current quarter
Filing year
2026
Fiscal year
0
Why it matters
Quality management needed
Signal category
Operations

Topics and mentions

Regions named

  • US

Extraction

Confidence
High
Relevance
90%
Sentiment
Negative
Detected
Aug 11, 2026
signal_type
sec-10q
signal_subtype
qualityIssue

Use this data

Get every 10-Q signal for BD and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at BD this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/e01855ee-16dc-4759-8e9e-1347f86defaa returns this record as JSON. POST /v1/companies/enrich returns every signal for bd.com.

{
  "signal_id": "e01855ee-16dc-4759-8e9e-1347f86defaa",
  "signal_type": "sec-10q",
  "signal_subtype": "qualityIssue",
  "detected_at": "2026-08-11T08:07:08.57+00:00",
  "company": {
    "name": "BD",
    "domain": "bd.com"
  },
  "data": {
    "detail": "The company faces significant regulatory risk with its U.S. infusion pump business, with the FDA having authority to halt manufacturing or order recalls. This creates intense pressure to ensure quality, compliance, and supply chain continuity for the product's re-introduction to the U.S. market.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "summary": "BDX's Alaris infusion pump business continues to operate under an FDA Consent Decree.",
    "excerpts": "As a result of the CareFusion acquisition, our U.S. infusion pump business is operating under a Consent Decree with the FDA. The Consent Decree authorizes the FDA, in the event of any violations in the future, to order our U.S. infusion pump business to cease manufacturing and distributing products, recall products or take other actions, and order the payment of significant monetary damages if the business subject to the decree fails to comply with any provision of the Consent Decree.",
    "relevance": 0.9,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/10795/000001079526000035/bdx-20260630.htm",
    "filing_date": "2026-08-06",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Quality management needed",
    "signal_category": "operations",
    "regions_mentioned": [
      "US"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.